Lamivudine and Tenofovir Disoproxil Fumarate

FDA Drug Profile — CIMDUO

Lamivudine and Tenofovir Disoproxil Fumarate is listed in the FDA National Drug Code directory with 1 NDC code, marketed under brand name including CIMDUO. Available dosage form: tablet, film coated.

Drug details

Generic Name
Lamivudine and Tenofovir Disoproxil Fumarate
Brand Names
CIMDUO
Application Number
NDA022141
Sponsor
Viatris Specialty LLC
NDC Codes
1
Dosage Forms
TABLET, FILM COATED
Routes
ORAL
Active Ingredients
LAMIVUDINE, TENOFOVIR DISOPROXIL FUMARATE

Indications and Usage

1 INDICATIONS AND USAGE CIMDUO ® (lamivudine and tenofovir disoproxil fumarate) is indicated in combination with other antiretroviral agents for the treatment of human immunodeficiency virus type 1 (HIV-1) infection in adult and pediatric patients weighing at least 35 kg. CIMDUO is a two-drug combination of lamivudine (3TC) and tenofovir disoproxil fumarate (TDF), both nucleo(t)side reverse transcriptase inhibitors and is indicated in combination with other antiretroviral agents for the treatment of human immunodeficiency virus type 1 (HIV-1) infection in adult and pediatric patients weighing at least 35 kg. ( 1 )

Sources: openFDA, FDA Data Dashboard, FDA.gov. Report a data issue: hello@regdatalab.com.